君實生物-B(01877.HK):科創板上市申請的審核狀態為"已問詢"
格隆匯12月23日丨君實生物-B(01877.HK)公佈,公司在中止審核期間已完成相關財務數據的更新,並於2019年12月18日向上交所提交了恢復審核申請,上交所同意自2019年12月20日起恢復對公司首次公開發行股票並在科創板上市的審核。
目前,公司首次公開發行股票並在科創板上市申請的審核狀態為"已問詢"。
根據《全國中小企業股份轉讓系統業務規則(試行)》的規定,公司股票將繼續在全國中小企業股份轉讓系統暫停轉讓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.